Literature DB >> 15652407

The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro.

P Sacerdote1, C Martucci, A Vaccani, F Bariselli, A E Panerai, A Colombo, D Parolaro, P Massi.   

Abstract

Cannabidiol is the main nonpsychoactive component of marijuana. We examined the ability of in vivo and in vitro cannabidiol to interfere with the production of interleukin (IL)-12 and IL-10 by murine macrophages and to modulate macrophage chemotaxis. Cannabidiol added in vitro to peritoneal macrophages significantly increased IL-12 and decreased IL-10 production. The CB1 and CB2 receptor antagonists prevented this modulation. Macrophages from animals treated with cannabidiol at the dose of 30 mg kg(-1) either orally or i.p. produced higher levels of IL-12 and lower levels of IL-10 in comparison to controls, and the CB receptor antagonists did not prevent these effects. Cannabidiol dose-dependently decreased fMLP-induced chemotaxis of macrophages, and the CB2 receptor antagonist prevented this decrease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15652407     DOI: 10.1016/j.jneuroim.2004.10.003

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  33 in total

1.  Formation of B and T cell subsets require the cannabinoid receptor CB2.

Authors:  David Ziring; Bo Wei; Peter Velazquez; Matthew Schrage; Nancy E Buckley; Jonathan Braun
Journal:  Immunogenetics       Date:  2006-08-19       Impact factor: 2.846

Review 2.  CB2 receptor-mediated migration of immune cells: it can go either way.

Authors:  A M Miller; N Stella
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 3.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 4.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

5.  Cannabidiol attenuates delayed-type hypersensitivity reactions via suppressing T-cell and macrophage reactivity.

Authors:  Der-zen LIU; Chieh-min HU; Chung-hsiung HUANG; Shiaw-pyng WEY; Tong-rong JAN
Journal:  Acta Pharmacol Sin       Date:  2010-11-01       Impact factor: 6.150

6.  Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages.

Authors:  Cataldo Martucci; Silvia Franchi; Elisa Giannini; Hui Tian; Pietro Melchiorri; Lucia Negri; Paola Sacerdote
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

7.  Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.

Authors:  Hao Pan; Partha Mukhopadhyay; Mohanraj Rajesh; Vivek Patel; Bani Mukhopadhyay; Bin Gao; György Haskó; Pál Pacher
Journal:  J Pharmacol Exp Ther       Date:  2008-12-12       Impact factor: 4.030

8.  Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway.

Authors:  Yi-Jie Liu; Hong-Bo Fan; Yi Jin; Chun-Guang Ren; Xiao-E Jia; Lei Wang; Yi Chen; Mei Dong; Kang-Yong Zhu; Zhi-Wei Dong; Bai-Xin Ye; Zhong Zhong; Min Deng; Ting Xi Liu; Ruibao Ren
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

Review 9.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 10.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.